March 03, 2026 — 14 articles reviewed
This cycle’s dominant themes center on age-dependent cognitive effects of cannabis, the persistent gap between rescheduling momentum and functional regulatory frameworks, and emerging pharmaceutical-grade standardization that could reshape clinical confidence in cannabinoid prescribing. Taken together, these stories illustrate a field caught between accelerating clinical evidence and a policy infrastructure that continues to lag behind what patients and clinicians actually need.
The evidence base for cannabis medicine is maturing faster than the regulatory and social structures built to contain it. Our job as clinicians is to keep prescribing with the data we have, push for the data we need, and never let policy confusion substitute for clinical judgment.
Digest-Level Clinical Commentary
Clinical Reflection
As we observe accelerating clinical evidence for age-dependent cannabis effects alongside persistent regulatory fragmentation, I’m increasingly counseling patients that our prescribing decisions must account for neurodevelopmental windows that extend into the mid-20s, even as legal access expands faster than our ability to establish standardized dosing protocols. The disconnect between rescheduling momentum and functional clinical infrastructure means I’m spending more time than ever establishing individualized risk-benefit frameworks with patients rather than relying on evidence-based guidelines that simply don’t yet exist at scale. This gap between what the science shows and what our healthcare systems can actually implement remains the central tension in my practice today.
Clinical Perspective
The emerging evidence base increasingly documents age-dependent cognitive effects of cannabis, particularly regarding developmental windows in adolescence and early adulthood where neurotoxicity appears most pronounced. However, clinical practice remains constrained by a significant lag between evolving research findings and regulatory frameworks that have not yet adapted to support evidence-based risk stratification or patient counseling guidelines. This gap between scientific understanding and policy infrastructure creates practical challenges for clinicians attempting to provide informed recommendations within the current legal and institutional landscape.
Clinical Research
Cannabis PolicyRegulatory AffairsCognitive Effects💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: